This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo


Oral formulations of primidone.

Drugs List

  • primidone 250mg tablets
  • primidone 50mg tablets
  • PRIMIDONE ASPIRE 250mg tablets
  • PRIMIDONE ASPIRE 50mg tablets
  • PRIMIDONE TEVA 250mg tablets
  • PRIMIDONE TEVA 50mg tablets
  • Therapeutic Indications


    Epilepsy - except absence seizures
    Management of essential tremor

    Primidone is indicated in the management of grand mal and psychomotor (temporal lobe) epilepsy. It is also of value in the management of focal or Jacksonian seizures, myoclonic jerks and akinetic attacks.

    Management of essential tremor.


    Treatment should be always be managed on an individual basis. In many patients it will be possible to use primidone alone, but in some it may need to be combined with other anticonvulsants or with supporting therapy.


    Primidone should be started at the lowest possible dose in the evening and thereafter the dose should be increased in a stepwise manner to minimise adverse reactions.

    The average daily maintenance dose is 750 to 1500mg.

    Treatment should be started with 125mg once daily, late in the evening. The daily dosage should be increased by 125mg every 3 days until the patient is receiving 500mg daily. Thereafter, increase the daily dosage by 250mg every 3 days until control is obtained or the maximum tolerated dose is being given. This may be as much as 1500mg per day.

    The total daily dose is usually best administered in two equal amounts, one in the morning and one in the evening. In certain patients it may be considered advisable to give a larger dose when seizures are more frequent. For instance, if the attacks are nocturnal then all or most of the daily dose should be given in the evening or if the attacks are associated with some particular event such as menstruation, a slight increase in the appropriate dose is often beneficial.

    Essential tremor
    Initially a dose of 50mg daily should be introduced in a single intake late afternoon. The daily dose (given in two divided doses) should be increased gradually over a 2 to 3 week period until remission of symptoms or the highest tolerated dose up to a maximum of 750mg daily is obtained.

    Patients with essential tremor who have not previously been exposed to anticonvulsants, or other drugs known to induce increased hepatic enzyme activity, may experience acute symptoms of intolerance to primidone, frequently characterised by nausea, vertigo and unsteadiness. It is therefore essential to start such patients at a low dose and titrate the dosage slowly.


    It is advisable to monitor elderly patients with reduced renal function during treatment, and consider a reduced dose.


    The average daily dose for children over 9 years
    750 to 1500mg

    The average daily dose for children 6 to 9 years
    750 to 1000mg

    The average daily dose for children 2 to 5 years
    500 to 750mg

    The average daily dose for children up to 2 years
    250 to 500mg

    Treatment should be started with 125mg once daily, late in the evening. The daily dosage should be increased by 125mg every 3 days until the patient is receiving 500mg daily. Thereafter, increase the daily dosage by 250mg in children over the age of 9 and by 125mg in children under 9 years every 3 days until control is obtained or the maximum tolerated dose is being given.

    Patients with Renal Impairment

    The Renal Drug Handbook recommends no change in dose at a glomerular filtration rate (GFR) above 20ml/min. For GFR less than 20ml/min the following dose changes are suggested:

    GFR 10 to 20ml/min: Dose as in normal renal function, but avoid large doses.
    GFR less than 10ml/min: Reduce the dose by 25 to 50% initially, and avoid large single doses in patients.

    Additional Dosage Information

    Concomitant use/switch from other anticonvulsant treatments
    In the case of lack of efficacy of other anticonvulsant treatments or in case of adverse reactions induced by these drugs, primidone may be used to increase the efficacy of the existing/underlying treatment or to replace it. Initially, primidone should be added to the previous treatment following a method of progressive dose increase. When an acceptable therapeutic effect is reached and primidone dose has reached at least half of the previous dose, the discontinuation of the previous treatment can be attempted. The dose adjustment is to be performed for 2 weeks during which it may be necessary to increase primidone doses to maintain a good control.


    Acute porphyria
    Severe respiratory depression

    Precautions and Warnings

    Children under 18 years
    Females of childbearing potential
    Glucose-galactose malabsorption syndrome
    Hepatic impairment
    History of alcohol abuse
    History of drug misuse
    Lactose intolerance
    Renal impairment
    Respiratory impairment

    Advise ability to drive/operate machinery may be affected by side effects
    Increased risk of osteomalacia; consider vitamin D supplement
    Prescribe by manufacturer's product to ensure seizure control maintenance
    Some formulations contain lactose
    Monitor closely for skin reactions
    Monitor for signs of suicide ideation or behaviour
    Neonate exposed in utero: Monitor for neonatal withdrawal syndrome
    Tolerance and dependence may occur
    Potential for withdrawal symptoms
    Avoid abrupt withdrawal
    Discontinue and do not restart if severe cutaneous adverse reactions occur
    Discontinue if megaloblastic anaemia develops
    Consider dose reduction in renal impairment
    Consider dose reduction in severe hepatic impairment
    Start treatment at lowest recommended dose
    Advise patient not to take St John's wort concurrently
    Advise patient to avoid alcohol during treatment
    Advise that effects are potentiated by CNS depressants (including alcohol)
    Female: Ensure adequate contraception during treatment
    Neonate exposed in utero: Administer vitamin K at birth
    Pregnancy: Administer vitamin K in the last few weeks of pregnancy
    Pregnancy: Advise taking folate supplement as risk of neural tube defects
    Advise patient/carers to report signs of suicide ideation or behaviour

    Introduction of an anti-epileptic drug may be rarely followed by recrudescence of the crises of by occurrence of a new type of crisis for the patient. For primidone, causes of theses aggravations may be: a choice of treatment inadequate for the crises or the epileptic syndrome in this patient, a change of the concomitant anti-epileptic treatment or a pharmacokinetic interaction, a toxicity or overdose.

    Antiepileptic treatment is associated with a increased risk of suicidal thoughts and behaviour. Patients should be alert to any mood changes, distressing thoughts, or feelings about suicide or harming themselves at any point during treatment.

    Pregnancy and Lactation


    Primidone is contraindicated during pregnancy.

    The manufacturer does not recommend using primidone during pregnancy unless clearly necessary. Available reports indicate teratogenic effects including congenital heart disease, cleft palate, spina bifida, microencephaly and anencephaly. If primidone is used during pregnancy, the minimal effective dose should be used.

    Pregnant patients should be given vitamin K1 through the last month of pregnancy up to the time of delivery as anticonvulsant therapy in pregnancy has been associated with coagulation disorders in the neonates. In the absence of such pre-treatment, 10mg vitamin K1 may be given to the mother at the time of delivery and 1mg should be given immediately to the neonate at risk.


    Use primidone with caution during breastfeeding.

    The manufacturer does not recommend primidone during breastfeeding. There is a risk of sedation during the neonatal immediate period which can cause difficulties in suckling, and therefore poor weight gain.

    If primidone is required by the mother, it is not a reason to discontinue breastfeeding. However, the infant must be monitored for drowsiness, adequate nursing and weight gain, and developmental milestones, especially in younger, exclusively breastfed infants and when using combinations of anticonvulsant drugs. Measurement of an infant serum level might help rule out of toxicity if there is a concern (LactMed, 2022).

    Side Effects

    Allergic reaction
    Blood dyscrasias
    Cardiovascular depression
    Decrease in bone mineral density
    Drug rash with eosinophilia and systemic symptoms (DRESS)
    Dupuytren's contracture
    Exfoliative dermatitis
    Folate deficiency
    Gamma glutamyl transferase (GGT) increased
    Hypersensitivity syndrome
    Increase in alkaline phosphatase
    Increased risk of fractures
    Increases in hepatic enzymes
    Lupus erythematosus
    Maculopapular rash
    Megaloblastic anaemia
    Morbilliform eruption
    Personality change
    Psychotic symptoms
    Respiratory depression
    Scarlatiniform rash
    Severe cutaneous adverse reactions
    Stevens-Johnson syndrome
    Suicidal tendencies
    Toxic epidermal necrolysis
    Visual disturbances


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: November 2019

    Reference Sources

    Summary of Product Characteristics: Primidone Aspire 50mg tablets. Aspire Pharma Ltd. Revised August 2022.
    Summary of Product Characteristics: Primidone Aspire 250mg tablets. Aspire Pharma Ltd. Revised August 2022.
    Summary of Product Characteristics: Primidone Auden 50mg tablets. Teva UK Ltd. Revised November 2018.
    Summary of Product Characteristics: Primidone Auden 250mg tablets. Teva UK Ltd. Revised November 2018.

    The Renal Drug Handbook. Fifth Edition (2019) ed. Ashley, C and Dunleavy, A, Radcliffe Publishing Ltd, London.

    MHRA Drug Safety Update Vol 2, Issue 9, April 2009
    Antiepileptics: adverse effects on bone
    Available at:
    Last accessed: 15/10/10

    MHRA Drug Safety Update Vol 2, Issue 1, August 2008
    Antiepileptics: risk of suicidal thoughts and behaviour
    Available at:
    Last accessed: 15/10/10

    NICE Evidence Services Available at: Last accessed: 07 November 2019

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Primidone Last revised: 18 January 2022.
    Last accessed: 17 January 2023.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.